P 2007

Methods for inhibiting protein kinases

GUZI, Timothy, Kamil PARUCH, Michael DWYER, David PARRY, Lianyun ZHAO et. al.

Basic information

Original name

Methods for inhibiting protein kinases

Name in Czech

Methods for inhibiting protein kinases

Authors

GUZI, Timothy, Kamil PARUCH, Michael DWYER, David PARRY, Lianyun ZHAO, Patrick CURRAN, David BELANGER, Blake HAMANN, Panduranga REDDY, Arshad SIDDIQUI and Praveen TADIKONDA

Edition

Number: US 2007/0105864 A1, Publisher: United States Patent and Trademark Office, Place of publication: USA, Owner's name: Schering-Plough, 2007

Other information

Language

English

Type of outcome

Patent

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Organization unit

Faculty of Science

Keywords (in Czech)

kinases; cancer; inhibitor

Keywords in English

kinases; cancer; inhibitor

Tags

Změněno: 25/6/2009 15:02, doc. Mgr. Kamil Paruch, Ph.D.

Abstract

ORIG CZ

V originále

The invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim-1 kinase, and tyrosine kinase using imidazo[1,2-a]pyrazine compds. of formula I and methods of treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with protein kinases using such compds. Compds. of formula I wherein R is H, halo, (un)substituted (hetero)aryl, (un)substituted cycloalkyl, (un)substituted arylalkyl, (un)substituted heterocyclyl, etc.; R1 is H, halo, and alkyl; R2 is alkyl, (un)substituted (hetero)aryl(alkyl), alkenyl, alkynyl, etc.; R3 is H, (un)substituted (hetero)aryl(alkyl), (un)substituted heterocyclyl(alkyl), (un)substituted (hetero)cycloalkyl, etc.; and their pharmaceutically acceptable salts, solvates, esters, and prodrugs thereof are claimed. Example compd. II was prepd. by amination of 3-(1-methylpyrazol-4-yl)-7-methylsulfonylimidazo[1,2-a]pyrazine with 3-(methylsulfonyl)aniline. All the invention compds. were evaluated for their protein kinase inhibitory activity (data given).

In Czech

viz Anotace